Franco M Buonaguro and Sam M Mbulaiteye, Editors-in-Chief of Infectious Agents & Cancer, would like to invite you to submit your manuscript to a new thematic series, entitled “Burkitt Lymphoma, Beyond Discoveries” which will be published in the journal.
Burkitt Lymphoma (BL) is an aggressive non-Hodgkin lymphoma (NHL) that was first described by Dennis Burkitt in 1958 in Ugandan children. Since then, numerous breakthroughs, including the discovery of the Epstein-Barr virus (EBV), and its links to the disease, have been made. The most important of these discoveries has been the demonstration of curability of lymphoma which has re-invigorated efforts to use chemotherapy to treat cancer and helped establish some of the key principles of chemotherapy for treating cancers more broadly, including combined modality therapy, attention to tumor lysis syndrome, and treatment of sanctuary sites. In spite of this, fundamental questions about BL remain unanswered.
The series will explore what is currently known about BL from a multi-disciplinary perspective and discuss the outstanding questions about the role of malaria, HIV or EBV in BL, and whether it is feasible reduce BL incidence by preventing these diseases in populations where both co-exist.
Potential topics include, but are not limited to
• Clinical applications
• Pathology and pathogenesis of BL in developed and developing countries
Submissions will be welcomed that review or highlight recent discoveries using novel technologies (i.e. next generation sequencing along with new genome sequencing methods, including ChIP-Seq, RNA-Seq, miRNA). Those that identify novel molecularly targeted treatments or discovery of biomarkers for high-risk or response to treatment are especially welcome.
Please submit your manuscript via the online submission system for the journal, and state clearly in the covering letter that it is intended for this thematic series. Before submitting your manuscript, please read the ‘Instructions for authors’. Please direct any questions regarding journal selection or the series in general to email@example.com.